Rutgers iJOBS is excited to have biomedical graduate students and postdoctoral fellows completing the Board Certification in Medical Affairs Specialist program. iJOBS is funded by the NIH Broadening Experiences in Scientific Training (BEST) initiative with the goal of exposing PhD students and postdocs to careers outside of academia so they can make informed decisions about their futures. Many of our iJOBS trainees have expressed interest in a career in Medical Affairs within the pharmaceutical industry and the BCMAS program is a systematic mechanism for training scientific and clinical professionals in the topics related to this field.
A few weeks ago, the Food and Drug Administration (FDA), released a report establishing a final rule amending regulatory definitions of what is considered “intended use” for drugs which had originally required drug companies to include labeling for unapproved uses the drug company knew about. The FDA revised this in January stating that if a drug company has plans to promote a drug off-label based on the “totality of the evidence” then similar labeling was required.
Recently, several pharmaceutical industry experts in medical affairs and myself authored a paper discussing the importance of establishing a standard in medical affairs which you can read by clicking here
The Accreditation Council for Medical Affairs (ACMA) is a self-governing entity whose mission is to establish, certify, and maintain the competencies of qualified medical and scientific professionals who have a focus in Medical Affairs within the pharmaceutical and biotechnology industries. The council works collaboratively with other academic and industry